The Global HIV Vaccine Enterprise was established in 2003 as a collaborative global effort to promote the development of a safe and effective HIV vaccine. The Bill & Melinda Gates Foundation set out to advance this mission by contributing more than $287 million in support of HIV vaccine development and discovery. The Foundation awarded funds to eleven consortia that will focus on novel methods in HIV vaccine design and five central laboratories and data analysis facilities that will provide state-of-the-art technologies to evaluate HIV vaccine candidates.
Over the next 7 years, the Duke CHAVI-ID will build on the progress that was made by the CHAVI consortium and apply state-of-the-art technologies and both immunologic and virologic tools to improve rational HIV-1 vaccine design. The vaccine strategy of the Duke CHAVI-ID is based on identifying and targeting novel HIV-1 vulnerabilities to B, T and NK cell immune responses and using this information to design vaccines that will induce protective immunity at the time and location of HIV-1 transmission.